申萬宏源(06806.HK):申萬宏源證券對開源證券提起仲裁申請
格隆匯8月26日丨申萬宏源(06806.HK)公吿,2018年10月,申萬宏源證券管理的申銀萬國天天增1號集合資產管理計劃與開源證券管理的臻意7號定向資產管理計劃(以下簡稱“臻意7號”)開展債券質押式回購業務,開展了五筆債券質押式協議回購業務,合計本金105,960,000.00元。
2019年9月9日,開源證券管理的臻意7號在約定的到期日未履行正回購方的還款義務,構成實質性違約。為維護申萬宏源證券及委託人合法權益,申萬宏源證券代表資產管理計劃向上海國際仲裁中心提起仲裁,並於2021年8月23日知悉相關仲裁事項獲得受理。上述仲裁事項對發行人生產經營、財務狀況及償債能力無重大不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.